For research use only. Not for therapeutic Use.
CCG-1423（Cat No.:I002975）is a small molecule inhibitor that targets the RhoA signaling pathway, specifically interfering with the RhoA-mediated activation of serum response factor (SRF) and myocardin-related transcription factor (MRTF). This inhibition disrupts actin cytoskeleton dynamics, cell migration, and proliferation, making CCG-1423 valuable in cancer research. It has shown potential in reducing tumor growth and metastasis in preclinical studies by blocking key steps in the RhoA-MRTF signaling axis. Its ability to target this pathway makes it a promising compound for studying cancer metastasis and other diseases driven by abnormal cell motility and growth.
| Catalog Number | I002975 |
| CAS Number | 285986-88-1 |
| Synonyms | N-((1-((4-chlorophenyl)amino)-1-oxopropan-2-yl)oxy)-3,5-bis(trifluoromethyl)benzamide |
| Molecular Formula | C18H13ClF6N2O3 |
| Purity | ≥95% |
| Target | Rho |
| Solubility | DMSO: ≥ 26 mg/mL |
| Storage | Store at -20°C |
| IC50 | 1.5 uM |
| IUPAC Name | N-[1-(4-chloroanilino)-1-oxopropan-2-yl]oxy-3,5-bis(trifluoromethyl)benzamide |
| InChI | InChI=1S/C18H13ClF6N2O3/c1-9(15(28)26-14-4-2-13(19)3-5-14)30-27-16(29)10-6-11(17(20,21)22)8-12(7-10)18(23,24)25/h2-9H,1H3,(H,26,28)(H,27,29) |
| InChIKey | DSMXVSGJIDFLKP-UHFFFAOYSA-N |
| SMILES | CC(C(=O)NC1=CC=C(C=C1)Cl)ONC(=O)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F |
| Reference | </br>1:Stereospecific Inhibitory Effects of CCG-1423 on the Cellular Events Mediated by Myocardin-Related Transcription Factor A. Watanabe B, Minami S, Ishida H, Yoshioka R, Nakagawa Y, Morita T, Hayashi K.PLoS One. 2015 Aug 21;10(8):e0136242. doi: 10.1371/journal.pone.0136242. eCollection 2015. PMID: 26295164 Free PMC Article</br>2:RPEL proteins are the molecular targets for CCG-1423, an inhibitor of Rho signaling. Hayashi K, Watanabe B, Nakagawa Y, Minami S, Morita T.PLoS One. 2014 Feb 18;9(2):e89016. doi: 10.1371/journal.pone.0089016. eCollection 2014. PMID: 24558465 Free PMC Article</br>3:Design and synthesis of tag-free photoprobes for the identification of the molecular target for CCG-1423, a novel inhibitor of the Rho/MKL1/SRF signaling pathway. Bell JL, Haak AJ, Wade SM, Sun Y, Neubig RR, Larsen SD.Beilstein J Org Chem. 2013 May 21;9:966-73. doi: 10.3762/bjoc.9.111. Print 2013. PMID: 23766813 Free PMC Article</br>4:Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. Evelyn CR, Bell JL, Ryu JG, Wade SM, Kocab A, Harzdorf NL, Showalter HD, Neubig RR, Larsen SD.Bioorg Med Chem Lett. 2010 Jan 15;20(2):665-72. doi: 10.1016/j.bmcl.2009.11.056. Epub 2009 Nov 18. PMID: 19963382 Free PMC Article</br>5:CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Evelyn CR, Wade SM, Wang Q, Wu M, Iñiguez-Lluhí JA, Merajver SD, Neubig RR.Mol Cancer Ther. 2007 Aug;6(8):2249-60. PMID: 17699722 Free Article |
